Prikrina

Prikrina is a clinical-stage biotechnology company focused on developing novel therapies for patients suffering from hyperoxaluria and related kidney stone diseases. The company's lead program, PRK-001, is an orally delivered recombinant enzyme designed to degrade oxalate in the gastrointestinal tract before it can be absorbed into the bloodstream. By reducing systemic oxalate levels, Prikrina aims to prevent the formation of calcium oxalate crystals, which are the primary cause of kidney stones and progressive renal damage. The company's approach targets both primary hyperoxaluria, a rare genetic disorder, and enteric hyperoxaluria, which often results from malabsorption issues. Founded on research from the University of Florida, Prikrina is advancing its pipeline to address significant unmet needs in the nephrology and metabolic disease space.